Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Applied DNA Sciences Inc (APDN) - free report >>
Empire State Realty Trust, Inc. (ESRT) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Applied DNA Sciences Inc (APDN) - free report >>
Empire State Realty Trust, Inc. (ESRT) - free report >>
Image: Bigstock
New Strong Sell Stocks for December 18th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Empire State Realty Trust, Inc. (ESRT - Free Report) is a real estate investment trust that owns, manages, operates, acquires and repositions office and retail properties. The Zacks Consensus Estimate for its current year earnings has been revised 5.3% downward over the last 30 days.
The RealReal, Inc. (REAL - Free Report) operates an online marketplace for consigned luxury goods. The Zacks Consensus Estimate for its current year earnings has been revised 2.5% downward over the last 30 days.
Applied DNA Sciences, Inc. (APDN - Free Report) engages in polymerase chain reaction-based DNA manufacturing. The Zacks Consensus Estimate for its current year earnings has been revised 2% downward over the last 30 days.
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. The Zacks Consensus Estimate for its current year earnings has been revised 8.6% downward over the last 60 days.
SharpSpring, Inc. operates as a cloud-based marketing technology company. The Zacks Consensus Estimate for its current year earnings has been revised 78.6% downward over the last 60 days.
View the entire Zacks Rank #5 List.